Table 1 presents baseline patients’ demographic and tumor characteristics in the different groups of the entire cohort: 76.6% (n = 538) had no deleterious mutation (cohort A); 17.4% (n = 122) a deleterious BRCA1/2 mutation (cohort B): BRCA1- 69.7% (n = 85), BRCA2- 30.3% (n = 37); and 6% (n = 42) showed another deleterious mutation (cohort C). This evidence concerns the gene BRCA1 and neoplasm.